Barbara Seitz-Polski1, Christine Payré2, Damien Ambrosetti3, Laetitia Albano4, Elisabeth Cassuto-Viguier5, Marine Berguignat4, Ahmed Jeribi4, Marie-Christine Thouret6, Ghislaine Bernard7, Sylvia Benzaken7, Gérard Lambeau2, Vincent L M Esnault4. 1. Service de Néphrologie, Hôpital Pasteur, Université de Nice-Sophia Antipolis, Nice, France Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS et Université de Nice-Sophia Antipolis, Valbonne, France Laboratoire d'Immunologie, Hôpital l'Archet, Université de Nice-Sophia Antipolis, Nice, France. 2. Institut de Pharmacologie Moléculaire et Cellulaire, UMR 7275 CNRS et Université de Nice-Sophia Antipolis, Valbonne, France. 3. Service d'anatomopathologie, Hôpital Pasteur, Université Nice-Sophia Antipolis, Nice, France. 4. Service de Néphrologie, Hôpital Pasteur, Université de Nice-Sophia Antipolis, Nice, France. 5. Service de Néphrologie, Hôpital Pasteur, Université de Nice-Sophia Antipolis, Nice, France Service d'anatomopathologie, Hôpital Pasteur, Université Nice-Sophia Antipolis, Nice, France. 6. Service de Néphro-pédiatrie, Hôpital l'Archet, Université de Nice-Sophia Antipolis, Nice, France. 7. Laboratoire d'Immunologie, Hôpital l'Archet, Université de Nice-Sophia Antipolis, Nice, France.
Abstract
BACKGROUND: The predictive value of anti-M-type phospholipase A2 receptor (PLA2R1) autoantibodies for membranous nephropathy (MN) recurrence after renal transplantation remains controversial. METHODS: Our aim was to monitor anti-PLA2R1 IgG4 activity using a sensitive enzyme-linked immunosorbent assay in 15 kidney transplant recipients with MN, and to test the correlation between antibody titres and MN recurrence. RESULTS: Five patients never exhibited anti-PLA2R1 antibodies, and one of them relapsed. Ten patients (67%) had IgG4 anti-PLA2R1 antibodies at the time of transplantation and during follow-up. The presence of IgG4 anti-PLA2R1 antibodies at the time of kidney transplantation does not imply MN recurrence (P = 0.600, n = 15). However, a positive IgG4 anti-PLA2R1 activity during follow-up (>Month 6) was a significant risk factor for MN relapse (P = 0.0048, n = 10). Indeed, four patients had persistent IgG4 anti-PLA2R1 activity after transplantation and relapsed. Among them, one was successfully treated with rituximab. Another had persistently high IgG4 anti-PLA2R1 activity and exhibited a histological relapse but no proteinuria while on treatment with renin-angiotensin system inhibitors. In contrast, the six other patients who did not relapse exhibited a decrease of their IgG4 anti-PLA2R1 activity following transplant immunosuppression, including two with proteinuria due to biopsy-proven differential diagnoses. A weak transplant immunosuppressive regimen was also a risk factor of MN recurrence (P = 0.0048, n = 10). Indeed, the six patients who received both an induction therapy and a combined treatment with calcineurin inhibitors/mycophenolate exhibited a decrease of IgG4 anti-PLA2R1 activity and did not relapse, while the four patients who did not receive this strong immunosuppressive treatment association had persistently high IgG4 anti-PLA2R1 activity and relapsed. CONCLUSION: The monitoring of IgG4 anti-PLA2R1 titres during follow-up helps to predict MN recurrence, and a strong immunosuppressive treatment of anti-PLA2R1 positive patients may prevent recurrence.
BACKGROUND: The predictive value of anti-M-type phospholipase A2 receptor (PLA2R1) autoantibodies for membranous nephropathy (MN) recurrence after renal transplantation remains controversial. METHODS: Our aim was to monitor anti-PLA2R1 IgG4 activity using a sensitive enzyme-linked immunosorbent assay in 15 kidney transplant recipients with MN, and to test the correlation between antibody titres and MN recurrence. RESULTS: Five patients never exhibited anti-PLA2R1 antibodies, and one of them relapsed. Ten patients (67%) had IgG4 anti-PLA2R1 antibodies at the time of transplantation and during follow-up. The presence of IgG4 anti-PLA2R1 antibodies at the time of kidney transplantation does not imply MN recurrence (P = 0.600, n = 15). However, a positive IgG4 anti-PLA2R1 activity during follow-up (>Month 6) was a significant risk factor for MN relapse (P = 0.0048, n = 10). Indeed, four patients had persistent IgG4 anti-PLA2R1 activity after transplantation and relapsed. Among them, one was successfully treated with rituximab. Another had persistently high IgG4 anti-PLA2R1 activity and exhibited a histological relapse but no proteinuria while on treatment with renin-angiotensin system inhibitors. In contrast, the six other patients who did not relapse exhibited a decrease of their IgG4 anti-PLA2R1 activity following transplant immunosuppression, including two with proteinuria due to biopsy-proven differential diagnoses. A weak transplant immunosuppressive regimen was also a risk factor of MN recurrence (P = 0.0048, n = 10). Indeed, the six patients who received both an induction therapy and a combined treatment with calcineurin inhibitors/mycophenolate exhibited a decrease of IgG4 anti-PLA2R1 activity and did not relapse, while the four patients who did not receive this strong immunosuppressive treatment association had persistently high IgG4 anti-PLA2R1 activity and relapsed. CONCLUSION: The monitoring of IgG4 anti-PLA2R1 titres during follow-up helps to predict MN recurrence, and a strong immunosuppressive treatment of anti-PLA2R1 positive patients may prevent recurrence.
Authors: Nicola M Tomas; Laurence H Beck; Catherine Meyer-Schwesinger; Barbara Seitz-Polski; Hong Ma; Gunther Zahner; Guillaume Dolla; Elion Hoxha; Udo Helmchen; Anne-Sophie Dabert-Gay; Delphine Debayle; Michael Merchant; Jon Klein; David J Salant; Rolf A K Stahl; Gérard Lambeau Journal: N Engl J Med Date: 2014-11-13 Impact factor: 91.245
Authors: An S De Vriese; Richard J Glassock; Karl A Nath; Sanjeev Sethi; Fernando C Fervenza Journal: J Am Soc Nephrol Date: 2016-10-24 Impact factor: 10.121
Authors: A Kattah; R Ayalon; L H Beck; S Sethi; D G Sandor; F G Cosio; M J Gandhi; E C Lorenz; D J Salant; F C Fervenza Journal: Am J Transplant Date: 2015-03-12 Impact factor: 8.086
Authors: Barbara Seitz-Polski; Hanna Debiec; Alexandra Rousseau; Karine Dahan; Christelle Zaghrini; Christine Payré; Vincent L M Esnault; Gérard Lambeau; Pierre Ronco Journal: J Am Soc Nephrol Date: 2017-11-07 Impact factor: 10.121